A Non-Sofosbuvir–Based, All-Oral Regimen for Genotype 4 HCV Infection

All-oral treatment regimens for hepatitis C virus (HCV) infection are available for genotypes 1 to 3. However, for genotype 4 infection, which accounts for 13% of HCV infections worldwide, recommended treatment regimens still contain interferon. Now, in an industry-funded phase IIb study, investigators have evaluated the efficacy and safety of an interferon-free regimen for these patients.

Eighty-six treatment-naive, HCV genotype 4–infected patients without cirrhosis were randomized to receive a once-daily regimen of ombitasvir (an NS5A inhibitor; 25 mg) plus paritaprevir (an NS3/4A protease inhibitor; 150 mg) plus ritonavir (100 mg) with or without twice-daily ribavirin for 12 weeks. Also, 49 treatment-experienced patients received a 12-wee…